CuraGen's CEO Jonathan Rothberg Talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Sept. 25, 2001 The Wall Street Transcript has published an in-depth interview with Jonathan M. Rothberg The creator of this article, or someone who has substantially contributed to it, may have a conflict of interest regarding its subject matter. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. , Ph.D., Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CuraGen Corporation (Nasdaq:CRGN), in which he talks at length about the company's future. The entire 4,100-word interview is available free online at http://www.twst.com/ceos.htm. Dr. Rothberg gives an overview of the company. "CuraGen has positioned itself as a leading genomics-based biopharmaceutical company. Early on we identified an inflection point Inflection Point An event that changes the way we think and act. -Andy Grove, Founder of Intel. Notes: For example, the fall of the Berlin Wall was an inflection point in global politics and the commercialization of the Internet was an inflection point in technology. at the intersection of information technology and molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller . To that end, our first scientific advisor was from Intel Corporation (company) Intel Corporation - A US microelectronics manufacturer. They produced the Intel 4004, Intel 8080, Intel 8086, Intel 80186, Intel 80286, Intel 80386, Intel 486 and Pentium microprocessor families as well as many other integrated circuits and personal computer networking , and our second advisor was from Amgen. While other people were thinking about segmenting the genome genome: see genetics. genome all the genetic content contained within an organism. An organism's genome is made up of molecules of deoxyribonucleic acid (DNA) that form long strands that are tightly wound into chromosomes, which are found in the , we had always focused on the opportunity to turn the genome into products for treating unmet medical needs." Dr. Rothberg explains, "CuraGen is financially strong, having approximately $540 million in the bank, so we are negotiating strategic partnerships with a high degree of confidence. We are only interested in entering into collaborations that enable us to learn techniques that will make the company stronger, and help CuraGen move products through the clinical stages of development, and ultimately to market." Looking forward, Dr. Rothberg states, "I expect that over the coming years CuraGen's pharmaceutical pipeline of proteins, antibodies and small molecules will become one, two or three in the world. Our scientists are taking a comprehensive and systematic approach to understand how genes and proteins function in diabetes and obesity, cancer, inflammation, and in CNS See Continuous net settlement. CNS See continuous net settlement (CNS). disorders. The next three to five years are going to be the most important historically for developing treatments for complex diseases based upon the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. , and we have positioned CuraGen to systematically develop pharmaceutical products through the application of genomics. Our plan is to enter CuraGen's first products into the clinical phases of development next year." This interview is part of a 352-page Bear, Stearns & Company 14th Annual Healthcare Conference Issue available at http://www.twst.com/info/info418.htm or by calling 212/952-7433. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion